Microba Life Financials
| MAP Stock | 0.28 0.03 12.00% |
Microba | Select Account or Indicator |
Please note, the imprecision that can be found in Microba Life's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Microba Life Sciences. Check Microba Life's Beneish M Score to see the likelihood of Microba Life's management manipulating its earnings.
Microba Life Stock Summary
Microba Life competes with Champion Iron, Ironbark Capital, Fisher Paykel, Mount Gibson, and Sonic Healthcare. Microba Life is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | South Africa |
Specialization | Health Care, Health Care Equipment & Services |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU0000209868 |
| Business Address | 324 Queen Street, |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | microba.com |
| Phone | 61 13 0097 4621 |
You should never invest in Microba Life without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Microba Stock, because this is throwing your money away. Analyzing the key information contained in Microba Life's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Microba Life Key Financial Ratios
Microba Life's financial ratios allow both analysts and investors to convert raw data from Microba Life's financial statements into concise, actionable information that can be used to evaluate the performance of Microba Life over time and compare it to other companies across industries.| Revenue | 12.09 M | ||||
| Gross Profit | 5.91 M | ||||
| EBITDA | (17.1 M) | ||||
| Net Income | (19.94 M) | ||||
| Cash And Equivalents | 12.43 M |
Microba Life Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 18.5M | 39.5M | 47.0M | 58.0M | 66.7M | 34.4M | |
| Other Current Liab | 1.7M | 1.1M | 3.9M | 5.3M | 6.1M | 6.4M | |
| Net Debt | (12.8M) | (29.3M) | (30.9M) | (19.3M) | (17.4M) | (18.2M) | |
| Retained Earnings | (19.7M) | (31.2M) | (43.9M) | (63.8M) | (57.4M) | (54.6M) | |
| Accounts Payable | 353.5K | 813.2K | 3.0M | 3.7M | 4.3M | 4.5M | |
| Cash | 13.0M | 30.6M | 32.0M | 20.9M | 24.0M | 21.0M | |
| Net Receivables | 376.3K | 3.4M | 7.2M | 8.1M | 9.3M | 9.8M | |
| Long Term Debt Total | 245.4K | 66.8K | 483.8K | 234.1K | 269.2K | 287.6K | |
| Inventory | 513.3K | 360.0K | 644.4K | 2.2M | 2.6M | 2.7M | |
| Other Current Assets | 1.0M | 204.4K | 1.6M | 1.0M | 1.2M | 781.9K | |
| Total Liab | 3.5M | 5.9M | 8.2M | 16.8M | 19.3M | 20.3M | |
| Total Current Assets | 16.2M | 35.8M | 41.5M | 32.2M | 37.1M | 26.7M | |
| Cash And Equivalents | 49.8K | 50.3K | 204.4K | 12.4M | 14.3M | 15.0M | |
| Short Term Debt | 202.3K | 841.4K | 901.7K | 1.2M | 1.4M | 1.5M | |
| Intangible Assets | 246.3K | 853.9K | 2.8M | 13.4M | 15.4M | 16.2M | |
| Common Stock | 33.5M | 62.9M | 80.4M | 102.9M | 118.3M | 124.2M |
Microba Life Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | (6.5K) | 0.0 | 9.2K | 5.6K | 6.5K | 4.7K | |
| Interest Expense | 23.5K | 8.3K | 60.4K | 69.2K | 79.6K | 40.8K | |
| Total Revenue | 3.7M | 4.7M | 5.4M | 12.1M | 13.9M | 14.6M | |
| Gross Profit | (5.3M) | 2.4M | (6.8M) | (8.6M) | (7.7M) | (7.3M) | |
| Operating Income | (9.6M) | (11.5M) | (20.2M) | (26.8M) | (24.2M) | (23.0M) | |
| Ebit | (7.5M) | (11.4M) | (18.7M) | (20.0M) | (18.0M) | (18.9M) | |
| Ebitda | (6.3M) | (9.9M) | (17.1M) | (17.1M) | (15.4M) | (16.2M) | |
| Cost Of Revenue | 9.0M | 2.3M | 12.2M | 20.7M | 23.8M | 25.0M | |
| Income Before Tax | (7.5M) | (11.5M) | (18.8M) | (20.0M) | (18.0M) | (18.9M) | |
| Net Income | (7.5M) | (11.5M) | (12.7M) | (19.9M) | (17.9M) | (17.0M) | |
| Income Tax Expense | 1.0 | 9.2K | (6.1M) | (51.3K) | (46.2K) | (48.5K) | |
| Research Development | 1.5M | 5.4M | 9.3M | 10.8M | 12.5M | 13.1M |
Microba Life Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (172.5K) | 153.2K | (284.4K) | (310.6K) | (279.5K) | (265.5K) | |
| Change In Cash | 6.1M | 17.6M | 1.3M | (11.2M) | (10.0M) | (9.5M) | |
| Free Cash Flow | (7.9M) | (1.9M) | (15.4M) | (19.9M) | (18.0M) | (17.1M) | |
| Depreciation | 1.2M | 1.2M | 1.6M | 2.9M | 3.3M | 3.5M | |
| Other Non Cash Items | 3.6M | (910.1K) | 5.5M | 4.4M | 5.0M | 3.0M | |
| Capital Expenditures | 672.5K | 1.9M | 3.0M | 4.4M | 5.0M | 5.3M | |
| Net Income | (7.5M) | (11.5M) | (12.7M) | (19.9M) | (17.9M) | (17.0M) | |
| End Period Cash Flow | 13.0M | 30.6M | 32.0M | 20.9M | 24.0M | 21.0M |
Microba Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Microba Life's current stock value. Our valuation model uses many indicators to compare Microba Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Microba Life competition to find correlations between indicators driving Microba Life's intrinsic value. More Info.Microba Life Sciences is regarded second in return on equity category among its peers. It also is regarded second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Microba Life's earnings, one of the primary drivers of an investment's value.Microba Life Sciences Systematic Risk
Microba Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Microba Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Microba Life Sciences correlated with the market. If Beta is less than 0 Microba Life generally moves in the opposite direction as compared to the market. If Microba Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Microba Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Microba Life is generally in the same direction as the market. If Beta > 1 Microba Life moves generally in the same direction as, but more than the movement of the benchmark.
Microba Life Sciences Total Assets Over Time
Microba Life January 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Microba Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Microba Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Microba Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Microba Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Microba Life's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.8 | |||
| Information Ratio | 0.149 | |||
| Maximum Drawdown | 18.91 | |||
| Value At Risk | (5.88) | |||
| Potential Upside | 8.33 |
Additional Tools for Microba Stock Analysis
When running Microba Life's price analysis, check to measure Microba Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microba Life is operating at the current time. Most of Microba Life's value examination focuses on studying past and present price action to predict the probability of Microba Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microba Life's price. Additionally, you may evaluate how the addition of Microba Life to your portfolios can decrease your overall portfolio volatility.